Zacks Investment Research upgraded shares of 89bio (NASDAQ:ETNB) from a hold rating to a buy rating in a research report sent to investors on Wednesday, Zacks.com reports. Zacks Investment Research currently has $27.00 price target on the stock.
According to Zacks, “89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco. “
A number of other equities analysts have also recently issued reports on the company. BTIG Research increased their target price on 89bio from $51.00 to $58.00 and gave the stock a buy rating in a report on Tuesday, September 15th. Chardan Capital increased their price target on 89bio from $59.00 to $95.00 and gave the company a buy rating in a research report on Tuesday, September 15th. BofA Securities raised 89bio from a neutral rating to a buy rating and increased their price target for the company from $37.00 to $43.00 in a research report on Friday, September 25th. Piper Sandler began coverage on 89bio in a research report on Thursday, July 30th. They issued an overweight rating and a $54.00 price target for the company. Finally, BidaskClub lowered 89bio from a hold rating to a sell rating in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $52.33.
Shares of ETNB opened at $23.73 on Wednesday. 89bio has a 12-month low of $14.00 and a 12-month high of $47.25. The business’s fifty day moving average is $29.62 and its 200 day moving average is $27.75. The stock has a market cap of $399.95 million and a P/E ratio of -0.68.
89bio (NASDAQ:ETNB) last issued its earnings results on Thursday, August 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.03). Analysts anticipate that 89bio will post -3.1 earnings per share for the current fiscal year.
In other news, Director Orbimed Advisors Llc sold 275,000 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $28.00, for a total transaction of $7,700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 1,300,000 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were purchased at an average price of $28.00 per share, with a total value of $36,400,000.00. The disclosure for this purchase can be found here. Company insiders own 18.10% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in shares of 89bio by 8.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 31,286 shares of the company’s stock worth $624,000 after acquiring an additional 2,481 shares during the period. Point72 Asset Management L.P. bought a new position in 89bio in the 2nd quarter worth about $433,000. Bank of America Corp DE boosted its stake in 89bio by 56.7% in the 2nd quarter. Bank of America Corp DE now owns 16,423 shares of the company’s stock worth $327,000 after purchasing an additional 5,940 shares during the period. Logos Global Management LP boosted its stake in 89bio by 17.4% in the 2nd quarter. Logos Global Management LP now owns 290,000 shares of the company’s stock worth $5,780,000 after purchasing an additional 43,000 shares during the period. Finally, HC Advisors LLC bought a new position in 89bio in the 2nd quarter worth about $267,000. Institutional investors own 63.13% of the company’s stock.
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 that is being developed for the treatment of nonalcoholic steatohepatitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.